Biotech stocks ranked by a composite signal combining fund convergence, insider buying, catalyst proximity, short interest, and cash runway safety. Higher scores indicate more bullish signal alignment.
| # | Ticker | Company | Funds | Insider Buys | SI % | Catalyst | Runway | Score |
|---|---|---|---|---|---|---|---|---|
| 1 | WVE | Wave Life Sciences Ltd. | 5 | 4 | 9.1% | phase2 readout (87d) | — | 145Strong |
| 2 | TNGX | Tango Therapeutics Inc. | 5 | — | 38.0% | phase2 readout (60d) | — | 125Strong |
| 3 | OCUL | Ocular Therapeutix Inc. | 4 | — | 10.9% | phase3 readout (28d) | — | 121Strong |
| 4 | ORKA | Oruka Therapeutics, Inc. | 4 | — | 10.3% | phase2 readout (29d) | — | 120Strong |
| 5 | LENZ | LENZ Therapeutics, Inc. | 2 | 3 | 52.9% | — | — | 120Strong |
| 6 | CELC | Celcuity Inc. | 7 | — | 21.9% | phase3 readout (90d) | — | 117Strong |
| 7 | FDMT | 4D Molecular Therapeutics, Inc. | 4 | — | 21.1% | phase2 readout (90d) | — | 116Strong |
| 8 | STOK | Stoke Therapeutics, Inc. | 4 | — | 26.9% | phase3 readout (364d) | — | 112Strong |
| 9 | CNTA | Centessa Pharmaceuticals plc | 4 | — | 5.2% | phase2 readout (29d) | — | 110Strong |
| 10 | SYRE | Spyre Therapeutics, Inc. | 7 | — | 15.3% | phase2 readout (90d) | — | 110Strong |
| 11 | AAVXF | Abivax S.A. | 4 | — | — | phase3 readout (29d) | — | 110Strong |
| 12 | REPL | Replimune Group Inc. | 4 | — | 35.2% | — | — | 110Strong |
| 13 | APLS | Apellis Pharmaceuticals Inc. | 4 | — | 23.5% | phase2 readout (455d) | — | 109Strong |
| 14 | PRAX | Praxis Precision Medicines, Inc. | 7 | — | 13.5% | phase3 readout (90d) | — | 108Strong |
| 15 | APGE | Apogee Therapeutics Inc. | 5 | — | 23.2% | phase2 readout (243d) | — | 108Strong |
| 16 | PTCT | PTC Therapeutics Inc. | 4 | — | 12.2% | phase3 readout (90d) | — | 107Strong |
| 17 | ARWR | Arrowhead Pharmaceuticals Inc. | 5 | — | 11.4% | phase3 readout (60d) | — | 106Strong |
| 18 | COGT | Cogent Biosciences Inc. | 4 | — | 10.7% | phase2 readout (90d) | — | 106Strong |
| 19 | EWTX | Edgewise Therapeutics, Inc. | 4 | — | 10.3% | phase2 readout (90d) | — | 105Strong |
| 20 | OLMA | Olema Pharmaceuticals, Inc. | 5 | — | 10.2% | phase3 readout (90d) | — | 105Strong |
| 21 | NRIX | Nurix Therapeutics Inc. | 4 | — | 17.7% | phase2 readout (670d) | — | 103Strong |
| 22 | INSP | Inspire Medical Systems, Inc. | 5 | — | 17.0% | phase3 readout (333d) | — | 102Strong |
| 23 | NUVL | Nuvalent Inc. | 5 | — | 15.2% | phase2 readout (639d) | — | 100Strong |
| 24 | KYMR | Kymera Therapeutics Inc. | 8 | — | 14.6% | phase2 readout (455d) | — | 100Strong |
| 25 | BBIO | BridgeBio Pharma Inc. | 4 | — | 20.2% | — | — | 100Strong |
| 26 | IRON | Disc Medicine Inc. | 6 | — | 13.0% | phase2 readout (182d) | — | 98Moderate |
| 27 | PALI | PALISADE BIO, INC. | 4 | — | 17.6% | — | — | 98Moderate |
| 28 | RLAY | Relay Therapeutics Inc. | 4 | — | 13.4% | phase3 readout (760d) | — | 98Moderate |
| 29 | BCRX | BIOCRYST PHARMACEUTICALS INC | 5 | — | 15.0% | — | — | 95Moderate |
| 30 | CMPS | COMPASS Pathways plc | 4 | — | 5.7% | phase3 readout (90d) | — | 95Moderate |
| 31 | RVMD | Revolution Medicines Inc. | 4 | — | 7.7% | phase3 readout (90d) | — | 95Moderate |
| 32 | PCVX | Vaxcyte Inc. | 4 | — | 10.1% | phase3 readout (305d) | — | 95Moderate |
| 33 | ALKS | Alkermes plc | 3 | — | 17.9% | phase2 readout (90d) | — | 93Moderate |
| 34 | DYN | Dyne Therapeutics Inc. | 4 | — | 12.7% | — | — | 93Moderate |
| 35 | GLUE | Monte Rosa Therapeutics, Inc. | 3 | — | 16.9% | phase2 readout (60d) | — | 92Moderate |
| 36 | IVVD | Invivyd, Inc. | 5 | — | 10.5% | — | — | 91Moderate |
| 37 | TVTX | Travere Therapeutics Inc. | 3 | — | 14.6% | phase2 readout (90d) | — | 90Moderate |
| 38 | NGNE | Neurogene Inc. | 3 | — | 31.2% | — | — | 90Moderate |
| 39 | CGON | CG Oncology, Inc. | 3 | — | 13.2% | phase2 readout (90d) | — | 88Moderate |
| 40 | XNCR | Xencor Inc. | 3 | — | 21.6% | phase2 readout (245d) | — | 87Moderate |
| 41 | CTNM | Contineum Therapeutics, Inc. | 5 | — | 8.7% | phase2 readout (791d) | — | 85Moderate |
| 42 | XENE | Xenon Pharmaceuticals Inc. | 5 | — | 6.2% | phase3 readout (152d) | — | 85Moderate |
| 43 | MDLN | Medline Inc. | 4 | — | 3.9% | phase2 readout (243d) | — | 85Moderate |
| 44 | RNA | Avidity Biosciences Inc. | 4 | — | — | phase3 readout (152d) | — | 85Moderate |
| 45 | GPCR | Structure Therapeutics Inc. | 8 | — | 9.9% | phase2 readout (121d) | — | 85Moderate |
| 46 | BLTE | BELITE BIO, INC | 4 | — | 4.5% | phase3 readout (455d) | — | 85Moderate |
| 47 | EXAS | Exact Sciences Corporation | 4 | — | 3.9% | phase2 readout (258d) | — | 85Moderate |
| 48 | LEGN | Legend Biotech Corporation | 3 | — | 24.7% | — | — | 85Moderate |
| 49 | IMVT | Immunovant Inc. | 3 | — | 18.6% | phase3 readout (152d) | — | 84Moderate |
| 50 | TSHA | Taysha Gene Therapies, Inc. | 3 | — | 18.1% | phase2 readout (345d) | — | 83Moderate |
| 51 | KOD | Kodiak Sciences Inc. | 3 | — | 17.3% | phase3 readout (152d) | — | 82Moderate |
| 52 | LXEO | Lexeo Therapeutics, Inc. | 3 | — | 17.3% | phase2 readout (274d) | — | 82Moderate |
| 53 | JAZZ | Jazz Pharmaceuticals plc | 2 | — | 11.6% | phase2 readout (29d) | — | 82Moderate |
| 54 | IONS | Ionis Pharmaceuticals Inc. | 2 | — | 11.1% | phase3 readout (29d) | — | 81Moderate |
| 55 | KRYS | Krystal Biotech Inc. | 3 | — | 16.4% | phase3 readout (274d) | — | 81Moderate |
| 56 | QURE | uniQure N.V. | 3 | — | 20.6% | — | — | 81Moderate |
| 57 | SLNO | SOLENO THERAPEUTICS INC | 3 | — | 20.7% | — | — | 81Moderate |
| 58 | INCY | Incyte Corporation | 4 | — | 7.8% | — | — | 80Moderate |
| 59 | DXCM | DexCom Inc. | 5 | — | 5.5% | — | — | 80Moderate |
| 60 | PHVS | Pharvaris N.V. | 4 | — | 1.4% | — | — | 80Moderate |
| 61 | MNMD | Mind Medicine Inc. | 4 | — | — | — | — | 80Moderate |
| 62 | ELVN | Enliven Therapeutics, Inc. | 3 | — | 19.5% | — | — | 79Moderate |
| 63 | GRAL | GRAIL, Inc. | 3 | — | 18.0% | — | — | 78Moderate |
| 64 | SVRA | Savara Inc. | 3 | — | 13.4% | phase3 readout (455d) | — | 78Moderate |
| 65 | TERN | Terns Pharmaceuticals Inc. | 3 | — | 16.7% | — | — | 77Moderate |
| 66 | RYTM | Rhythm Pharmaceuticals Inc. | 3 | — | 12.2% | phase2 readout (213d) | — | 77Moderate |
| 67 | IMNM | Immunome Inc. | 3 | — | 16.3% | — | — | 76Moderate |
| 68 | LBRX | LB PHARMACEUTICALS INC | 3 | — | 11.4% | phase3 readout (455d) | — | 76Moderate |
| 69 | DSGN | Design Therapeutics, Inc. | 3 | — | 4.6% | phase3 readout (47d) | — | 75Moderate |
| 70 | EVMN | Evommune, Inc. | 3 | — | 9.3% | phase2 readout (60d) | — | 75Moderate |
| 71 | BSX | BOSTON SCIENTIFIC CORP | 3 | — | 1.7% | phase2 readout (61d) | — | 75Moderate |
| 72 | ENGNW | enGene Holdings Inc. | 3 | — | — | phase2 readout (90d) | — | 75Moderate |
| 73 | AMLX | Amylyx Pharmaceuticals, Inc. | 3 | — | 13.6% | — | — | 74Moderate |
| 74 | GHRS | GH Research PLC | 3 | — | 12.9% | — | — | 73Moderate |
| 75 | IMCR | Immunocore Holdings plc | 2 | — | 27.5% | phase2 readout (213d) | — | 72Moderate |
| 76 | TECX | Tectonic Therapeutic, Inc. | 2 | — | 26.1% | phase2 readout (191d) | — | 71Moderate |
| 77 | CLDX | Celldex Therapeutics Inc. | 2 | — | 16.4% | phase2 readout (90d) | — | 71Moderate |
| 78 | ABSI | Absci Corp | 2 | — | 29.7% | — | — | 70Moderate |
| 79 | RCUS | Arcus Biosciences Inc. | 2 | — | 9.7% | phase2 readout (29d) | — | 70Moderate |
| 80 | NBIX | Neurocrine Biosciences Inc. | 2 | — | 5.1% | phase3 readout (29d) | — | 70Moderate |
| 81 | MNPR | Monopar Therapeutics | 2 | — | 66.1% | — | — | 70Moderate |
| 82 | PTN | PALATIN TECHNOLOGIES INC | 3 | — | 10.2% | — | — | 70Moderate |
| 83 | RGEN | Repligen Corporation | 3 | — | 10.4% | — | — | 70Moderate |
| 84 | TMDX | TransMedics Group, Inc. | 2 | — | 41.5% | — | — | 70Moderate |
| 85 | UTHR | United Therapeutics Corporation | 2 | — | 8.6% | phase2 readout (29d) | — | 70Moderate |
| 86 | DNLI | Denali Therapeutics Inc. | 2 | — | 10.0% | phase2 readout (29d) | — | 70Moderate |
| 87 | VKTX | Viking Therapeutics Inc. | 2 | — | 25.1% | phase3 readout (456d) | — | 70Moderate |
| 88 | SDGR | Schrodinger Inc. | 2 | — | 27.9% | — | — | 68Moderate |
| 89 | BEAM | Beam Therapeutics Inc. | 2 | — | 23.5% | phase2 readout (274d) | — | 68Moderate |
| 90 | MIRM | Mirum Pharmaceuticals Inc. | 2 | — | 12.4% | phase2 readout (90d) | — | 67Moderate |
| 91 | ABCL | AbCellera Biologics Inc. | 2 | — | 21.5% | phase2 readout (333d) | — | 66Moderate |
| 92 | BCAX | Bicara Therapeutics Inc. | 2 | — | 20.8% | phase2 readout (760d) | — | 66Moderate |
| 93 | AGIO | Agios Pharmaceuticals Inc. | 2 | — | 10.6% | phase2 readout (60d) | — | 66Moderate |
| 94 | MPLT | MapLight Therapeutics, Inc. | 3 | — | 3.0% | phase2 readout (152d) | — | 65Moderate |
| 95 | ANRO | Alto Neuroscience, Inc. | 3 | — | 7.6% | phase2 readout (152d) | — | 65Moderate |
| 96 | INSM | Insmed Incorporated | 3 | — | 5.2% | phase3 readout (274d) | — | 65Moderate |
| 97 | KALV | KalVista Pharmaceuticals, Inc. | 1 | — | 43.3% | phase3 readout (90d) | — | 65Moderate |
| 98 | DRUG | BRIGHT MINDS BIOSCIENCES INC. | 3 | — | 7.0% | phase2 readout (243d) | — | 65Moderate |
| 99 | MDGL | Madrigal Pharmaceuticals Inc. | 2 | — | 19.8% | phase3 readout (274d) | — | 65Moderate |
| 100 | SABSW | SAB Biotherapeutics, Inc. | 3 | — | — | phase2 readout (608d) | — | 65Moderate |
| 101 | MLTX | MoonLake Immunotherapeutics | 2 | — | 20.0% | phase3 readout (289d) | — | 65Moderate |
| 102 | SPRY | ARS Pharmaceuticals, Inc. | 1 | — | 38.8% | phase2 readout (90d) | — | 65Moderate |
| 103 | JANX | Janux Therapeutics Inc. | 2 | — | 23.5% | — | — | 64Moderate |
| 104 | ORIC | ORIC Pharmaceuticals Inc. | 2 | — | 18.6% | phase2 readout (182d) | — | 64Moderate |
| 105 | EXEL | Exelixis Inc. | 1 | — | 14.2% | phase2 readout (11d) | — | 64Moderate |
| 106 | BBNX | Beta Bionics, Inc. | 2 | — | 17.8% | phase3 readout (182d) | — | 63Moderate |
| 107 | W | Wayfair Inc. | 2 | — | 23.5% | — | — | 63Moderate |
| 108 | AVTX | Avalo Therapeutics, Inc. | 2 | — | 22.2% | — | — | 62Moderate |
| 109 | EYPT | EyePoint, Inc. | 2 | — | 17.3% | phase3 readout (152d) | — | 62Moderate |
| 110 | SGRY | Surgery Partners, Inc. | 2 | — | 21.8% | — | — | 62Moderate |
| 111 | CRNX | Crinetics Pharmaceuticals Inc. | 2 | — | 16.5% | phase2 readout (213d) | — | 61Moderate |
| 112 | VEEV | VEEVA SYSTEMS INC | 3 | — | 3.7% | — | — | 60Moderate |
| 113 | CI | Cigna Group | 3 | — | 2.7% | — | — | 60Moderate |
| 114 | ROIV | Roivant Sciences Ltd. | 3 | — | 4.3% | — | — | 60Moderate |
| 115 | EW | Edwards Lifesciences Corp | 3 | — | 2.1% | — | — | 60Moderate |
| 116 | IMTX | Immatics N.V. | 3 | — | 5.5% | — | — | 60Moderate |
| 117 | IVEVF | Inventiva S.A. | 3 | — | — | — | — | 60Moderate |
| 118 | AKRO | Akero Therapeutics Inc. | 3 | — | — | — | — | 60Moderate |
| 119 | SMMT | Summit Therapeutics Inc. | 1 | — | 24.2% | phase2 readout (44d) | — | 59Weak |
| 120 | PI | IMPINJ INC | 2 | — | 19.1% | — | — | 59Weak |
| 121 | RAPP | Rapport Therapeutics, Inc. | 2 | — | 14.1% | phase2 readout (213d) | — | 59Weak |
| 122 | SRRK | Scholar Rock Holding Corp | 2 | — | 19.4% | — | — | 59Weak |
| 123 | ANNX | Annexon Biosciences Inc. | 2 | — | 12.9% | phase3 readout (213d) | — | 58Weak |
| 124 | VERA | Vera Therapeutics Inc. | 2 | — | 13.1% | phase2 readout (182d) | — | 58Weak |
| 125 | SION | Sionna Therapeutics, Inc. | 2 | — | 13.1% | phase2 readout (121d) | — | 58Weak |
| 126 | TARS | Tarsus Pharmaceuticals Inc. | 2 | — | 12.2% | phase2 readout (274d) | — | 57Weak |
| 127 | CYTK | Cytokinetics Incorporated | 2 | — | 16.4% | — | — | 56Weak |
| 128 | ZBIO | Zenas BioPharma, Inc. | 1 | — | 21.1% | phase3 readout (90d) | — | 56Weak |
| 129 | RARE | Ultragenyx Pharmaceutical Inc. | 2 | — | 10.6% | phase3 readout (121d) | — | 56Weak |
| 130 | PTGX | Protagonist Therapeutics Inc. | 2 | — | 15.1% | — | — | 55Weak |
| 131 | GH | Guardant Health Inc. | 2 | — | 9.1% | phase2 readout (60d) | — | 55Weak |
| 132 | IDCC | InterDigital, Inc. | 2 | — | 15.3% | — | — | 55Weak |
| 133 | VSTM | Verastem, Inc. | 1 | — | 20.4% | phase2 readout (90d) | — | 55Weak |
| 134 | IOVA | Iovance Biotherapeutics Inc. | 1 | — | 30.1% | phase2 readout (183d) | — | 55Weak |
| 135 | CAPR | CAPRICOR THERAPEUTICS, INC. | 2 | — | 14.2% | — | — | 54Weak |
| 136 | RDNT | RadNet, Inc. | 2 | — | 12.6% | — | — | 53Weak |
| 137 | CBIO | CRESCENT BIOPHARMA, INC. | 2 | — | 12.0% | — | — | 52Weak |
| 138 | RZLT | Rezolute, Inc. | 1 | — | 26.7% | phase3 readout (547d) | — | 52Weak |
| 139 | CTMX | CytomX Therapeutics Inc. | 2 | — | 12.4% | — | — | 52Weak |
| 140 | GERN | Geron Corporation | 2 | — | 10.3% | — | — | 50Weak |
| 141 | BIIB | Biogen Inc. | 1 | — | 3.8% | phase2 readout (29d) | — | 50Weak |
| 142 | OCSAW | Oculis Holding AG | 1 | — | — | phase3 readout (29d) | — | 50Weak |
| 143 | ADCT | ADC Therapeutics SA | 1 | — | 4.0% | phase2 readout (30d) | — | 50Weak |
| 144 | HIMS | Hims & Hers Health, Inc. | 1 | — | 45.2% | — | — | 50Weak |
| 145 | VITL | Vital Farms, Inc. | 1 | — | 30.6% | — | — | 50Weak |
| 146 | NTLA | Intellia Therapeutics Inc. | 1 | — | 37.4% | — | — | 50Weak |
| 147 | BNTX | BioNTech SE | 1 | — | 5.3% | phase2 readout (29d) | — | 50Weak |
| 148 | APLD | Applied Digital Corp. | 1 | — | 30.6% | — | — | 50Weak |
| 149 | SANA | Sana Biotechnology, Inc. | 1 | — | 38.2% | — | — | 50Weak |
| 150 | RXRX | Recursion Pharmaceuticals Inc. | 1 | — | 34.9% | — | — | 50Weak |
| 151 | EOSE | Eos Energy Enterprises, Inc. | 1 | — | 28.3% | — | — | 48Weak |
| 152 | IDYA | IDEAYA Biosciences Inc. | 1 | — | 13.1% | phase2 readout (82d) | — | 48Weak |
| 153 | ABEO | ABEONA THERAPEUTICS INC. | 1 | — | 28.1% | — | — | 48Weak |
| 154 | NUVB | Nuvation Bio Inc. | 1 | — | 23.0% | phase2 readout (364d) | — | 48Weak |
| 155 | TNYA | Tenaya Therapeutics, Inc. | 1 | — | 22.3% | phase2 readout (517d) | — | 47Weak |
| 156 | HCAT | Health Catalyst, Inc. | 1 | — | 11.3% | phase2 readout (60d) | — | 46Weak |
| 157 | SNDX | Syndax Pharmaceuticals Inc. | 1 | — | 26.1% | — | — | 46Weak |
| 158 | KNSA | Kiniksa Pharmaceuticals International, plc | 2 | — | 8.9% | phase3 readout (639d) | — | 45Weak |
| 159 | PRTO | Protara Therapeutics, Inc. | 2 | — | — | phase3 readout (455d) | — | 45Weak |
| 160 | IMMX | Immix Biopharma, Inc. | 2 | — | 7.2% | phase2 readout (274d) | — | 45Weak |
| 161 | XFOR | X4 Pharmaceuticals, Inc | 2 | — | 3.9% | phase3 readout (547d) | — | 45Weak |
| 162 | ALNY | Alnylam Pharmaceuticals Inc. | 2 | — | 4.3% | phase2 readout (422d) | — | 45Weak |
| 163 | XZO | Exzeo Group, Inc. | 1 | 1 | 1.9% | — | — | 45Weak |
| 164 | HELP | CYBIN INC. | 2 | — | — | phase3 readout (152d) | — | 45Weak |
| 165 | CSTL | CASTLE BIOSCIENCES INC | 2 | — | 5.5% | phase3 readout (547d) | — | 45Weak |
| 166 | TENX | TENAX THERAPEUTICS, INC. | 2 | — | 0.9% | phase3 readout (213d) | — | 45Weak |
| 167 | GKOS | Glaukos Corporation | 2 | — | 6.3% | phase2 readout (182d) | — | 45Weak |
| 168 | ISRG | Intuitive Surgical Inc. | 2 | — | 1.8% | phase3 readout (394d) | — | 45Weak |
| 169 | PEPG | PepGen Inc. | 2 | — | 6.2% | phase2 readout (152d) | — | 45Weak |
| 170 | ACAD | ACADIA Pharmaceuticals Inc. | 2 | — | 7.9% | phase2 readout (274d) | — | 45Weak |
| 171 | SYK | STRYKER CORP | 2 | — | 1.1% | phase2 readout (274d) | — | 45Weak |
| 172 | ERAS | Erasca Inc. | 2 | — | 9.5% | phase3 readout (760d) | — | 45Weak |
| 173 | ZLAB | Zai Lab Ltd | 2 | — | 5.0% | phase3 readout (347d) | — | 45Weak |
| 174 | MAZE | Maze Therapeutics, Inc. | 2 | — | 8.9% | phase2 readout (182d) | — | 45Weak |
| 175 | MBX | MBX Biosciences, Inc. | 2 | — | 9.7% | phase2 readout (421d) | — | 45Weak |
| 176 | TBBB | BBB FOODS INC | 1 | — | 25.2% | — | — | 45Weak |
| 177 | BEIGF | BeOne Medicines Ltd. | 2 | — | — | phase3 readout (121d) | — | 45Weak |
| 178 | LPTH | LIGHTPATH TECHNOLOGIES INC | 1 | 1 | 6.2% | — | — | 45Weak |
| 179 | ACRV | Acrivon Therapeutics, Inc. | 1 | — | 20.0% | phase2 readout (213d) | — | 45Weak |
| 180 | SEI | Solaris Energy Infrastructure, Inc. | 1 | — | 24.4% | — | — | 44Weak |
| 181 | TYRA | Tyra Biosciences, Inc. | 1 | — | 18.6% | phase2 readout (243d) | — | 44Weak |
| 182 | TEM | Tempus AI, Inc. | 1 | — | 18.8% | phase2 readout (274d) | — | 44Weak |
| 183 | INBX | Inhibrx Biosciences, Inc. | 1 | — | 17.5% | phase2 readout (212d) | — | 43Weak |
| 184 | URGN | UroGen Pharma Ltd. | 1 | — | 18.0% | phase3 readout (213d) | — | 43Weak |
| 185 | PGEN | Precigen Inc. | 1 | — | 17.4% | phase2 readout (669d) | — | 42Weak |
| 186 | TNDM | TANDEM DIABETES CARE INC | 1 | — | 21.3% | — | — | 41Weak |
| 187 | HROW | HARROW, INC. | 1 | — | 21.1% | — | — | 41Weak |
| 188 | ENOV | Enovis CORP | 1 | — | 20.9% | — | — | 41Weak |
| 189 | ANDG | Andersen Group Inc. | 1 | — | 20.8% | — | — | 41Weak |
| 190 | CORT | Corcept Therapeutics Inc. | 1 | — | 16.5% | phase2 readout (152d) | — | 41Weak |
| 191 | GGAL | GRUPO FINANCIERO GALICIA SA | 1 | — | 20.7% | — | — | 41Weak |
| 192 | IKT | Inhibikase Therapeutics, Inc. | 1 | — | 20.9% | — | — | 41Weak |
| 193 | PHR | Phreesia, Inc. | 2 | — | 7.6% | — | — | 40Weak |
| 194 | VCYT | VERACYTE, INC. | 2 | — | 7.5% | — | — | 40Weak |
| 195 | LBRT | Liberty Energy Inc. | 2 | — | 9.5% | — | — | 40Weak |
| 196 | RMBS | RAMBUS INC | 2 | — | 8.7% | — | — | 40Weak |
| 197 | UNP | UNION PACIFIC CORP | 2 | — | 4.5% | — | — | 40Weak |
| 198 | JBIO | Jade Biosciences, Inc. | 2 | — | — | — | — | 40Weak |
| 199 | UNH | UNITEDHEALTH GROUP INC | 2 | — | 2.0% | — | — | 40Weak |
| 200 | AMD | ADVANCED MICRO DEVICES INC | 2 | — | 2.0% | — | — | 40Weak |
| 201 | INDV | Indivior Pharmaceuticals, Inc. | 2 | — | 9.8% | — | — | 40Weak |
| 202 | PLDGP | Prologis, Inc. | 2 | — | — | — | — | 40Weak |
| 203 | CAI | Caris Life Sciences, Inc. | 2 | — | 5.2% | — | — | 40Weak |
| 204 | LLY | ELI LILLY & Co | 2 | — | 0.9% | — | — | 40Weak |
| 205 | HNGE | Hinge Health, Inc. | 2 | — | 7.2% | — | — | 40Weak |
| 206 | OVID | Ovid Therapeutics Inc. | 2 | — | 4.6% | — | — | 40Weak |
| 207 | RLMD | RELMADA THERAPEUTICS, INC. | 2 | — | 5.1% | — | — | 40Weak |
| 208 | COHR | COHERENT CORP. | 2 | — | 5.1% | — | — | 40Weak |
| 209 | DGX | QUEST DIAGNOSTICS INC | 2 | — | 4.0% | — | — | 40Weak |
| 210 | DBVTF | DBV Technologies S.A. | 2 | — | — | — | — | 40Weak |
| 211 | TXG | 10x Genomics Inc. | 1 | — | 19.6% | — | — | 40Weak |
| 212 | TFC-PR | TRUIST FINANCIAL CORP | 2 | — | — | — | — | 40Weak |
| 213 | HTFL | Heartflow, Inc. | 2 | — | 6.6% | — | — | 40Weak |
| 214 | FHTX | Foghorn Therapeutics Inc. | 2 | — | 3.2% | — | — | 40Weak |
| 215 | PODD | INSULET CORP | 2 | — | 5.5% | — | — | 40Weak |
| 216 | NHC | NATIONAL HEALTHCARE CORP | 2 | — | 5.8% | — | — | 40Weak |
| 217 | EHC | Encompass Health Corp | 2 | — | 4.0% | — | — | 40Weak |
| 218 | TYL | TYLER TECHNOLOGIES INC | 2 | — | 4.8% | — | — | 40Weak |
| 219 | CAH | CARDINAL HEALTH INC | 2 | — | 3.0% | — | — | 40Weak |
| 220 | CERT | Certara Inc. | 1 | — | 19.9% | — | — | 40Weak |
| 221 | TER | TERADYNE, INC | 2 | — | 3.8% | — | — | 40Weak |
| 222 | DOCS | Doximity Inc. | 2 | — | 9.8% | — | — | 40Weak |
| 223 | NBIS | Nebius Group N.V. | 1 | — | 19.6% | — | — | 40Weak |
| 224 | SEPN | Septerna, Inc. | 2 | — | 8.0% | — | — | 40Weak |
| 225 | TCRX | TScan Therapeutics, Inc. | 2 | — | 4.0% | — | — | 40Weak |
| 226 | PRME | Prime Medicine, Inc. | 1 | — | 19.7% | — | — | 40Weak |
| 227 | DVA | DAVITA INC. | 1 | — | 19.2% | — | — | 39Weak |
| 228 | PRLD | Prelude Therapeutics Inc. | 1 | — | 19.0% | — | — | 39Weak |
| 229 | VIR | Vir Biotechnology, Inc. | 1 | — | 14.4% | phase2 readout (243d) | — | 39Weak |
| 230 | NKTR | Nektar Therapeutics | 1 | — | 13.0% | phase2 readout (639d) | — | 38Weak |
| 231 | ALMS | ALUMIS INC. | 1 | — | 12.9% | phase2 readout (91d) | — | 38Weak |
| 232 | LITE | Lumentum Holdings Inc. | 1 | — | 18.0% | — | — | 38Weak |
| 233 | OSIS | OSI SYSTEMS INC | 1 | — | 16.8% | — | — | 37Weak |
| 234 | ALH | Alliance Laundry Holdings Inc. | 1 | — | 16.9% | — | — | 37Weak |
| 235 | PENN | PENN Entertainment, Inc. | 1 | — | 16.6% | — | — | 37Weak |
| 236 | VSCO | Victoria's Secret & Co. | 1 | — | 16.1% | — | — | 36Weak |
| 237 | CLYM | Climb Bio, Inc. | 1 | — | 11.1% | phase2 readout (517d) | — | 36Weak |
| 238 | ARQT | Arcus Biosciences Inc. | 1 | — | 15.6% | — | — | 36Weak |
| 239 | AZTA | Azenta Inc. | 1 | — | 16.4% | — | — | 36Weak |
| 240 | TBPH | Theravance Biopharma Inc. | 1 | — | 16.1% | — | — | 36Weak |
| 241 | ACLX | Arcellx Inc. | 1 | — | 10.9% | phase2 readout (274d) | — | 36Weak |
| 242 | EVH | Evolent Health, Inc. | 1 | — | 16.5% | — | — | 36Weak |
| 243 | CGEM | Cullinan Therapeutics, Inc. | 1 | — | 15.9% | — | — | 36Weak |
| 244 | KURA | Kura Oncology, Inc. | 1 | — | 16.3% | — | — | 36Weak |
| 245 | CCCC | C4 Therapeutics Inc. | 1 | — | 14.7% | — | — | 35Weak |
| 246 | IMAX | IMAX CORP | 1 | — | 15.2% | — | — | 35Weak |
| 247 | NPCE | NeuroPace Inc | 1 | — | 4.7% | phase2 readout (60d) | — | 35Weak |
| 248 | ABBV | AbbVie Inc. | 1 | — | 1.4% | phase3 readout (60d) | — | 35Weak |
| 249 | ITGR | Integer Holdings Corp | 1 | — | 15.4% | — | — | 35Weak |
| 250 | TRVI | Trevi Therapeutics, Inc. | 1 | — | 14.7% | — | — | 35Weak |
| 251 | ACIU | AC Immune SA | 1 | — | 6.3% | phase2 readout (90d) | — | 35Weak |
| 252 | TKO | TKO Group Holdings, Inc. | 1 | — | 14.0% | — | — | 34Weak |
| 253 | LCII | LCI INDUSTRIES | 1 | — | 14.2% | — | — | 34Weak |
| 254 | NP | Neptune Insurance Holdings Inc. | 1 | — | 13.9% | — | — | 34Weak |
| 255 | KMX | CARMAX INC | 1 | — | 13.7% | — | — | 34Weak |
| 256 | PRCT | PROCEPT BioRobotics Corp | 1 | — | 13.6% | — | — | 34Weak |
| 257 | RXST | RxSight Inc. | 1 | — | 12.9% | — | — | 33Weak |
| 258 | FSLY | Fastly, Inc. | 1 | — | 12.5% | — | — | 33Weak |
| 259 | CDE | Coeur Mining, Inc. | 1 | — | 12.6% | — | — | 33Weak |
| 260 | GLOB | Globant S.A. | 1 | — | 13.3% | — | — | 33Weak |
| 261 | MLYS | Mineralys Therapeutics, Inc. | 1 | — | 13.4% | — | — | 33Weak |
| 262 | PSIX | POWER SOLUTIONS INTERNATIONAL, INC. | 1 | — | 13.0% | — | — | 33Weak |
| 263 | GPI | GROUP 1 AUTOMOTIVE INC | 1 | — | 13.2% | — | — | 33Weak |
| 264 | SGMT | Sagimet Biosciences Inc. | 1 | — | 12.8% | — | — | 33Weak |
| 265 | BRCB | Black Rock Coffee Bar, Inc. | 1 | — | 12.4% | — | — | 32Weak |
| 266 | BROS | Dutch Bros Inc. | 1 | — | 12.1% | — | — | 32Weak |
| 267 | ATEC | Alphatec Holdings, Inc. | 1 | — | 12.2% | — | — | 32Weak |
| 268 | FIGS | FIGS, Inc. | 1 | — | 11.8% | — | — | 32Weak |
| 269 | POOL | POOL CORP | 1 | — | 11.9% | — | — | 32Weak |
| 270 | BE | Bloom Energy Corp | 1 | — | 11.6% | — | — | 32Weak |
| 271 | ALHC | Alignment Healthcare, Inc. | 1 | — | 11.8% | — | — | 32Weak |
| 272 | EOLS | Evolus, Inc. | 1 | — | 11.9% | — | — | 32Weak |
| 273 | IBIO | iBio, Inc. | 1 | — | 12.2% | — | — | 32Weak |
| 274 | FLGT | Fulgent Genetics Inc. | 1 | — | 12.3% | — | — | 32Weak |
| 275 | TTAN | ServiceTitan, Inc. | 1 | — | 12.2% | — | — | 32Weak |
| 276 | CAMT | CAMTEK LTD | 1 | — | 11.8% | — | — | 32Weak |
| 277 | ELDN | Eledon Pharmaceuticals, Inc. | 1 | — | 12.1% | — | — | 32Weak |
| 278 | PCOR | PROCORE TECHNOLOGIES, INC. | 1 | — | 11.8% | — | — | 32Weak |
| 279 | AMRC | Ameresco, Inc. | 1 | — | 10.7% | — | — | 31Weak |
| 280 | XMTR | Xometry, Inc. | 1 | — | 11.3% | — | — | 31Weak |
| 281 | WAY | Waystar Holding Corp. | 1 | — | 10.7% | — | — | 31Weak |
| 282 | BNTC | Benitec Biopharma Inc. | 1 | — | 11.1% | — | — | 31Weak |
| 283 | CARG | CarGurus, Inc. | 1 | — | 10.9% | — | — | 31Weak |
| 284 | EMBC | Embecta Corp. | 1 | — | 11.3% | — | — | 31Weak |
| 285 | CECO | CECO ENVIRONMENTAL CORP | 1 | — | 10.8% | — | — | 31Weak |
| 286 | RANI | Rani Therapeutics Holdings, Inc. | 1 | — | 11.2% | — | — | 31Weak |
| 287 | LNTH | Lantheus Holdings Inc. | 1 | — | 11.5% | — | — | 31Weak |
| 288 | NTAP | NetApp, Inc. | 1 | — | 10.8% | — | — | 31Weak |
| 289 | SOFI | SoFi Technologies, Inc. | 1 | — | 11.1% | — | — | 31Weak |
| 290 | LGN | Legence Corp. | 1 | — | 10.9% | — | — | 31Weak |
| 291 | SHLS | Shoals Technologies Group, Inc. | 1 | — | 10.9% | — | — | 31Weak |
| 292 | GTLB | Gitlab Inc. | 1 | — | 10.6% | — | — | 31Weak |
| 293 | ASMB | ASSEMBLY BIOSCIENCES, INC. | 1 | — | 11.2% | — | — | 31Weak |
| 294 | KYTX | Kyverna Therapeutics, Inc. | 1 | — | 10.2% | — | — | 30Weak |
| 295 | ABG | ASBURY AUTOMOTIVE GROUP INC | 1 | — | 10.3% | — | — | 30Weak |
| 296 | MMS | MAXIMUS, INC. | 1 | — | 10.2% | — | — | 30Weak |
| 297 | KLRS | Kalaris Therapeutics, Inc. | 1 | — | 10.3% | — | — | 30Weak |
| 298 | VOR | Vor Biopharma Inc. | 1 | — | 9.1% | phase3 readout (425d) | — | 25 |
| 299 | ZYME | Zymeworks Inc. | 1 | — | 8.2% | phase3 readout (455d) | — | 25 |
| 300 | MNKD | MannKind Corporation | 1 | — | 7.5% | phase2 readout (243d) | — | 25 |
| 301 | VYGR | Voyager Therapeutics Inc. | 1 | — | 6.3% | phase2 readout (425d) | — | 25 |
| 302 | ASND | Ascendis Pharma A/S | 1 | — | 7.5% | phase2 readout (274d) | — | 25 |
| 303 | NTRA | Natera Inc. | 1 | — | 2.4% | phase3 readout (274d) | — | 25 |
| 304 | TPTX | Turning Point Therapeutics Inc. | 1 | — | — | phase2 readout (182d) | — | 25 |
| 305 | ALGS | Aligos Therapeutics, Inc. | 1 | — | 5.6% | phase2 readout (364d) | — | 25 |
| 306 | ARGX | argenx SE | 1 | — | 3.4% | phase2 readout (121d) | — | 25 |
| 307 | AXSM | Axsome Therapeutics Inc. | 1 | — | 6.4% | phase2 readout (244d) | — | 25 |
| 308 | SKYE | Skye Bioscience, Inc. | 1 | — | 6.8% | phase2 readout (233d) | — | 25 |
| 309 | VTVT | vTv Therapeutics Inc. | 1 | — | 2.7% | phase3 readout (182d) | — | 25 |
| 310 | MOLN | MOLECULAR PARTNERS AG | 1 | — | 0.1% | phase2 readout (639d) | — | 25 |
| 311 | HD | HOME DEPOT, INC. | 1 | — | 1.0% | — | — | 20 |
| 312 | HLI | HOULIHAN LOKEY, INC. | 1 | — | 2.4% | — | — | 20 |
| 313 | EVR | Evercore Inc. | 1 | — | 1.6% | — | — | 20 |
| 314 | WLDN | Willdan Group, Inc. | 1 | — | 6.9% | — | — | 20 |
| 315 | AWI | ARMSTRONG WORLD INDUSTRIES INC | 1 | — | 3.3% | — | — | 20 |
| 316 | ONTO | ONTO INNOVATION INC. | 1 | — | 2.5% | — | — | 20 |
| 317 | VALE | Vale S.A. | 1 | — | 1.4% | — | — | 20 |
| 318 | LASR | NLIGHT, INC. | 1 | — | 4.6% | — | — | 20 |
| 319 | CPRT | COPART INC | 1 | — | 4.4% | — | — | 20 |
| 320 | TNL | Travel & Leisure Co. | 1 | — | 5.7% | — | — | 20 |
| 321 | AR | ANTERO RESOURCES Corp | 1 | — | 3.9% | — | — | 20 |
| 322 | EMBJ | EMBRAER S.A. | 1 | — | 1.3% | — | — | 20 |
| 323 | SHOO | STEVEN MADDEN, LTD. | 1 | — | 9.2% | — | — | 20 |
| 324 | COF-PN | CAPITAL ONE FINANCIAL CORP | 1 | — | — | — | — | 20 |
| 325 | ORA | ORMAT TECHNOLOGIES, INC. | 1 | — | 7.4% | — | — | 20 |
| 326 | VSOGF | Vista Energy, S.A.B. de C.V. | 1 | — | — | — | — | 20 |
| 327 | HUBS | HUBSPOT INC | 1 | — | 5.6% | — | — | 20 |
| 328 | PRLB | Proto Labs Inc | 1 | — | 3.5% | — | — | 20 |
| 329 | MTZ | MASTEC INC | 1 | — | 4.1% | — | — | 20 |
| 330 | MYRG | MYR GROUP INC. | 1 | — | 5.6% | — | — | 20 |
| 331 | TRDA | Entrada Therapeutics, Inc. | 1 | — | 4.4% | — | — | 20 |
| 332 | WFRD | Weatherford International plc | 1 | — | 7.8% | — | — | 20 |
| 333 | KALA | KALA BIO, Inc. | 1 | — | 0.8% | — | — | 20 |
| 334 | BLLN | BillionToOne, Inc. | 1 | — | 7.7% | — | — | 20 |
| 335 | BLD | TopBuild Corp | 1 | — | 6.1% | — | — | 20 |
| 336 | TRPCF | Trip.com Group Ltd | 1 | — | — | — | — | 20 |
| 337 | MU | MICRON TECHNOLOGY INC | 1 | — | 2.6% | — | — | 20 |
| 338 | BEAGR | Bold Eagle Acquisition Corp. | 1 | — | — | — | — | 20 |
| 339 | XERS | Xeris Biopharma Holdings, Inc. | 1 | — | 9.8% | — | — | 20 |
| 340 | WWD | Woodward, Inc. | 1 | — | 1.1% | — | — | 20 |
| 341 | CPA | Copa Holdings, S.A. | 1 | — | 5.1% | — | — | 20 |
| 342 | DLTR | DOLLAR TREE, INC. | 1 | — | 7.8% | — | — | 20 |
| 343 | ALSN | Allison Transmission Holdings Inc | 1 | — | 3.3% | — | — | 20 |
| 344 | CPS | Cooper-Standard Holdings Inc. | 1 | — | 3.8% | — | — | 20 |
| 345 | DNMXW | Dynamix Corp III | 1 | — | — | — | — | 20 |
| 346 | CAT | CATERPILLAR INC | 1 | — | 1.6% | — | — | 20 |
| 347 | FEIM | FREQUENCY ELECTRONICS INC | 1 | — | 9.6% | — | — | 20 |
| 348 | FULC | Fulcrum Therapeutics Inc. | 1 | — | 9.9% | — | — | 20 |
| 349 | IAG | IAMGOLD CORP | 1 | — | — | — | — | 20 |
| 350 | NI | NISOURCE INC. | 1 | — | 3.2% | — | — | 20 |
| 351 | CAEP | Cantor Equity Partners III, Inc. | 1 | — | — | — | — | 20 |
| 352 | PSMT | PRICESMART INC | 1 | — | 9.2% | — | — | 20 |
| 353 | BLFS | BIOLIFE SOLUTIONS INC | 1 | — | 9.1% | — | — | 20 |
| 354 | AFL | AFLAC INC | 1 | — | 2.1% | — | — | 20 |
| 355 | KIDS | ORTHOPEDIATRICS CORP | 1 | — | 5.5% | — | — | 20 |
| 356 | CRS | CARPENTER TECHNOLOGY CORP | 1 | — | 5.5% | — | — | 20 |
| 357 | CASY | CASEYS GENERAL STORES INC | 1 | — | 2.9% | — | — | 20 |
| 358 | HCMAW | HCM III ACQUISITION CORP. | 1 | — | — | — | — | 20 |
| 359 | INTC | INTEL CORP | 1 | — | 2.3% | — | — | 20 |
| 360 | DTIL | PRECISION BIOSCIENCES INC | 1 | — | 5.7% | — | — | 20 |
| 361 | INVLW | Innventure, Inc. | 1 | — | — | — | — | 20 |
| 362 | KEYS | Keysight Technologies, Inc. | 1 | — | 1.5% | — | — | 20 |
| 363 | WEC | WEC ENERGY GROUP, INC. | 1 | — | 5.2% | — | — | 20 |
| 364 | GMED | GLOBUS MEDICAL INC | 1 | — | 2.7% | — | — | 20 |
| 365 | NXT | Nextpower Inc. | 1 | — | 5.4% | — | — | 20 |
| 366 | QGEN | QIAGEN N.V. | 1 | — | 3.4% | — | — | 20 |
| 367 | MAMA | Mama's Creations, Inc. | 1 | — | 7.3% | — | — | 20 |
| 368 | AMGN | Amgen Inc. | 1 | — | 2.7% | — | — | 20 |
| 369 | APTV | Aptiv PLC | 1 | — | 4.3% | — | — | 20 |
| 370 | AUROW | Aurora Innovation, Inc. | 1 | — | — | — | — | 20 |
| 371 | AXON | AXON ENTERPRISE, INC. | 1 | — | 3.7% | — | — | 20 |
| 372 | BRKRP | BRUKER CORP | 1 | — | — | — | — | 20 |
| 373 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | 1 | — | 8.7% | — | — | 20 |
| 374 | PANW | Palo Alto Networks Inc | 1 | — | 3.1% | — | — | 20 |
| 375 | NSPR | InspireMD, Inc. | 1 | — | 0.1% | — | — | 20 |
| 376 | CBRE | CBRE GROUP, INC. | 1 | — | 1.4% | — | — | 20 |
| 377 | CHWY | Chewy, Inc. | 1 | — | 6.8% | — | — | 20 |
| 378 | FIX | COMFORT SYSTEMS USA INC | 1 | — | 2.6% | — | — | 20 |
| 379 | PFE | PFIZER INC | 1 | — | 2.3% | — | — | 20 |
| 380 | RBA | RB GLOBAL INC. | 1 | — | 6.8% | — | — | 20 |
| 381 | ROK | ROCKWELL AUTOMATION, INC | 1 | — | 2.9% | — | — | 20 |
| 382 | ROL | ROLLINS INC | 1 | — | 3.1% | — | — | 20 |
| 383 | RBRK | Rubrik, Inc. | 1 | — | 9.3% | — | — | 20 |
| 384 | DECK | DECKERS OUTDOOR CORP | 1 | — | 3.9% | — | — | 20 |
| 385 | ATAI | Atai Beckley N.V. | 1 | — | 5.7% | — | — | 20 |
| 386 | AXGN | Axogen, Inc. | 1 | — | 6.0% | — | — | 20 |
| 387 | AZO | AUTOZONE INC | 1 | — | 2.2% | — | — | 20 |
| 388 | OKTA | Okta, Inc. | 1 | — | 4.4% | — | — | 20 |
| 389 | CVS | CVS HEALTH Corp | 1 | — | 1.4% | — | — | 20 |
| 390 | CEG | Constellation Energy Corp | 1 | — | 2.9% | — | — | 20 |
| 391 | VST | Vistra Corp. | 1 | — | 3.0% | — | — | 20 |
| 392 | FANG | Diamondback Energy, Inc. | 1 | — | 5.1% | — | — | 20 |
| 393 | RSMDF | RESMED INC | 1 | — | — | — | — | 20 |
| 394 | AXP | AMERICAN EXPRESS CO | 1 | — | 2.1% | — | — | 20 |
| 395 | BKR | Baker Hughes Co | 1 | — | 2.9% | — | — | 20 |
| 396 | ALXO | ALX ONCOLOGY HOLDINGS INC | 1 | — | 1.1% | — | — | 20 |
| 397 | DELL | Dell Technologies Inc. | 1 | — | 9.0% | — | — | 20 |
| 398 | ADUS | Addus HomeCare Corp | 1 | — | 6.7% | — | — | 20 |
| 399 | SPGI | S&P Global Inc. | 1 | — | 1.3% | — | — | 20 |
| 400 | FTDR | Frontdoor, Inc. | 1 | — | 4.6% | — | — | 20 |
| 401 | PWR | QUANTA SERVICES, INC. | 1 | — | 3.4% | — | — | 20 |
| 402 | IOT | Samsara Inc. | 1 | — | 9.1% | — | — | 20 |
| 403 | CAMP | Camp4 Therapeutics Corp | 1 | — | 1.3% | — | — | 20 |
| 404 | MREO | Mereo BioPharma Group plc | 1 | — | 9.9% | — | — | 20 |
| 405 | ARDX | Ardelyx Inc. | 1 | — | 10.0% | — | — | 20 |
| 406 | ARVN | Arvinas Inc. | 1 | — | 7.6% | — | — | 20 |
| 407 | ALURW | ALLURION TECHNOLOGIES, INC. | 1 | — | — | — | — | 20 |
| 408 | GDRX | GoodRx Holdings Inc. | 1 | — | 9.5% | — | — | 20 |
| 409 | APXTW | Apex Treasury Corp | 1 | — | — | — | — | 20 |
| 410 | INTU | INTUIT INC. | 1 | — | 3.0% | — | — | 20 |
| 411 | AAPL | Apple Inc. | 1 | — | 0.8% | — | — | 20 |
| 412 | HQY | HEALTHEQUITY, INC. | 1 | — | 4.4% | — | — | 20 |
| 413 | TRUP | TRUPANION, INC. | 1 | — | 10.0% | — | — | 20 |
| 414 | ANET | Arista Networks, Inc. | 1 | — | 1.5% | — | — | 20 |
| 415 | GILD | Gilead Sciences Inc. | 1 | — | 1.6% | — | — | 20 |
| 416 | LATAW | Galata Acquisition Corp. II | 1 | — | — | — | — | 20 |
| 417 | CFLT | Confluent, Inc. | 1 | — | 9.1% | — | — | 20 |
| 418 | LMRI | Lumexa Imaging Holdings, Inc. | 1 | — | 1.1% | — | — | 20 |
| 419 | MRK | Merck & Co., Inc. | 1 | — | 1.3% | — | — | 20 |
| 420 | MRCY | MERCURY SYSTEMS INC | 1 | — | 7.8% | — | — | 20 |
| 421 | MIR | Mirion Technologies, Inc. | 1 | — | 9.0% | — | — | 20 |
| 422 | ITUB | Itau Unibanco Holding S.A. | 1 | — | 0.4% | — | — | 20 |
| 423 | DTM | DT Midstream, Inc. | 1 | — | 4.7% | — | — | 20 |
| 424 | DT | Dynatrace, Inc. | 1 | — | 3.5% | — | — | 20 |
| 425 | SGI | SOMNIGROUP INTERNATIONAL INC. | 1 | — | 3.1% | — | — | 20 |
| 426 | MSCI | MSCI Inc. | 1 | — | 1.8% | — | — | 20 |
| 427 | ECL | ECOLAB INC. | 1 | — | 1.2% | — | — | 20 |
| 428 | QXO-PB | QXO, Inc. | 1 | — | — | — | — | 20 |
| 429 | HVMCW | Highview Merger Corp. | 1 | — | — | — | — | 20 |
| 430 | PLRX | Pliant Therapeutics Inc. | 1 | — | 6.3% | — | — | 20 |
| 431 | ESI | Element Solutions Inc | 1 | — | 5.7% | — | — | 20 |
| 432 | FN | Fabrinet | 1 | — | 7.5% | — | — | 20 |
| 433 | FAST | FASTENAL CO | 1 | — | 3.1% | — | — | 20 |
| 434 | MIAX | MIAMI INTERNATIONAL HOLDINGS, INC. | 1 | — | — | — | — | 20 |
| 435 | ILMN | Illumina Inc. | 1 | — | 7.4% | — | — | 20 |
| 436 | LAB | STANDARD BIOTOOLS INC. | 1 | — | 3.3% | — | — | 20 |
| 437 | TLN | Talen Energy Corp | 1 | — | 7.3% | — | — | 20 |
| 438 | FITBM | FIFTH THIRD BANCORP | 1 | — | — | — | — | 20 |
| 439 | FTNT | Fortinet, Inc. | 1 | — | 3.1% | — | — | 20 |
| 440 | GRMN | GARMIN LTD | 1 | — | 1.9% | — | — | 20 |
| 441 | MANH | MANHATTAN ASSOCIATES INC | 1 | — | 5.3% | — | — | 20 |
| 442 | ROP | ROPER TECHNOLOGIES INC | 1 | — | 2.6% | — | — | 20 |
| 443 | RPRX | Royalty Pharma plc | 1 | — | 2.8% | — | — | 20 |
| 444 | ULTA | Ulta Beauty, Inc. | 1 | — | 5.7% | — | — | 20 |
| 445 | UCTT | Ultra Clean Holdings, Inc. | 1 | — | 9.2% | — | — | 20 |
| 446 | CGNX | COGNEX CORP | 1 | — | 2.7% | — | — | 20 |
| 447 | CGNT | Cognyte Software Ltd. | 1 | — | 0.8% | — | — | 20 |
| 448 | GENVR | Gen Digital Inc. | 1 | — | — | — | — | 20 |
| 449 | GNRC | GENERAC HOLDINGS INC. | 1 | — | — | — | — | 20 |
| 450 | LH | LABCORP HOLDINGS INC. | 1 | — | 4.7% | — | — | 20 |
| 451 | MASI | Masimo Corporation | 1 | — | 7.6% | — | — | 20 |
| 452 | MMSI | MERIT MEDICAL SYSTEMS INC | 1 | — | — | — | — | 20 |
| 453 | HAL | HALLIBURTON CO | 1 | — | 5.9% | — | — | 20 |
| 454 | MDXG | MiMedx Group Inc. | 1 | — | 5.2% | — | — | 20 |
| 455 | LSCC | LATTICE SEMICONDUCTOR CORP | 1 | — | 8.5% | — | — | 20 |
| 456 | LIFX | Life360, Inc. | 1 | — | — | — | — | 20 |
| 457 | MKC-V | MCCORMICK & CO INC | 1 | — | — | — | — | 20 |
| 458 | MDT | Medtronic plc | 1 | — | 1.3% | — | — | 20 |
| 459 | MDB | MongoDB, Inc. | 1 | — | 4.6% | — | — | 20 |
| 460 | NDAQ | NASDAQ, INC. | 1 | — | 1.6% | — | — | 20 |
| 461 | NEE-PV | NEXTERA ENERGY INC | 1 | — | — | — | — | 20 |
| 462 | NRG | NRG ENERGY, INC. | 1 | — | 2.6% | — | — | 20 |
| 463 | NVDA | NVIDIA CORP | 1 | — | 1.0% | — | — | 20 |
| 464 | SRE | SEMPRA | 1 | — | 1.4% | — | — | 20 |
| 465 | NOW | ServiceNow, Inc. | 1 | — | 2.7% | — | — | 20 |
| 466 | SHOP | SHOPIFY INC. | 1 | — | 1.5% | — | — | 20 |
| 467 | SITM | SITIME Corp | 1 | — | 7.3% | — | — | 20 |
| 468 | STLD | STEEL DYNAMICS INC | 1 | — | 3.1% | — | — | 20 |
| 469 | STE | STERIS plc | 1 | — | 2.0% | — | — | 20 |
| 470 | TOST | Toast, Inc. | 1 | — | 4.9% | — | — | 20 |
| 471 | TOL | Toll Brothers, Inc. | 1 | — | 4.1% | — | — | 20 |
| 472 | TT | Trane Technologies plc | 1 | — | 1.4% | — | — | 20 |
| 473 | ALNT | ALLIENT INC | 1 | — | 5.7% | — | — | 20 |
| 474 | VRT | Vertiv Holdings Co | 1 | — | 2.4% | — | — | 20 |
| 475 | XYL | Xylem Inc. | 1 | — | 2.1% | — | — | 20 |
| 476 | ZTS | Zoetis Inc. | 1 | — | 3.7% | — | — | 20 |
| 477 | ZS | Zscaler, Inc. | 1 | — | 7.5% | — | — | 20 |
| 478 | AORT | ARTIVION, INC. | 1 | — | 4.3% | — | — | 20 |
| 479 | AZN | ASTRAZENECA PLC | 1 | — | 0.1% | — | — | 20 |
| 480 | ATROB | ASTRONICS CORP | 1 | — | — | — | — | 20 |
| 481 | ATI | ATI INC | 1 | — | 3.2% | — | — | 20 |
| 482 | ATAT | Atour Lifestyle Holdings Ltd | 1 | — | 4.0% | — | — | 20 |
| 483 | AVGO | Broadcom Inc. | 1 | — | 1.1% | — | — | 20 |
| 484 | DOO | BRP Inc. | 1 | — | — | — | — | 20 |
| 485 | BDCIW | BTC Development Corp. | 1 | — | — | — | — | 20 |
| 486 | CCXIW | Churchill Capital Corp XI | 1 | — | — | — | — | 20 |
| 487 | NET | Cloudflare, Inc. | 1 | — | 2.9% | — | — | 20 |
| 488 | BAP | CREDICORP LTD | 1 | — | 1.8% | — | — | 20 |
| 489 | CUBB | Customers Bancorp, Inc. | 1 | — | — | — | — | 20 |
| 490 | DQ | DAQO NEW ENERGY CORP. | 1 | — | 5.9% | — | — | 20 |
| 491 | FTAIN | FTAI Aviation Ltd. | 1 | — | — | — | — | 20 |
| 492 | GIL | Gildan Activewear Inc. | 1 | — | 3.3% | — | — | 20 |
| 493 | GRABW | Grab Holdings Ltd | 1 | — | — | — | — | 20 |
| 494 | GHM | GRAHAM CORP | 1 | — | 3.8% | — | — | 20 |
| 495 | HDB | HDFC BANK LTD | 1 | — | 0.2% | — | — | 20 |
| 496 | HLIO | HELIOS TECHNOLOGIES, INC. | 1 | — | 3.7% | — | — | 20 |
| 497 | DYORU | Insight Digital Partners II | 1 | — | — | — | — | 20 |
| 498 | LECO | LINCOLN ELECTRIC HOLDINGS INC | 1 | — | 1.2% | — | — | 20 |
| 499 | MTSI | MACOM Technology Solutions Holdings, Inc. | 1 | — | — | — | — | 20 |
| 500 | NEO | NEOGENOMICS INC | 1 | — | 8.9% | — | — | 20 |
| 501 | NXE | NexGen Energy Ltd. | 1 | — | — | — | — | 20 |
| 502 | PRM | Perimeter Solutions, Inc. | 1 | — | 3.1% | — | — | 20 |
| 503 | HOOD | Robinhood Markets, Inc. | 1 | — | 3.9% | — | — | 20 |
| 504 | ROKU | ROKU, INC | 1 | — | 5.9% | — | — | 20 |
| 505 | SAIA | SAIA INC | 1 | — | 5.7% | — | — | 20 |
| 506 | SE | Sea Ltd | 1 | — | 6.6% | — | — | 20 |
| 507 | SMTC | SEMTECH CORP | 1 | — | 5.7% | — | — | 20 |
| 508 | SPY | SPDR S&P 500 ETF TRUST | 1 | — | — | — | — | 20 |
| 509 | SPXC | SPX Technologies, Inc. | 1 | — | 2.6% | — | — | 20 |
| 510 | SNEX | StoneX Group Inc. | 1 | — | 5.1% | — | — | 20 |
| 511 | TE-WT | T1 Energy Inc. | 1 | — | — | — | — | 20 |
| 512 | TCMD | TACTILE SYSTEMS TECHNOLOGY INC | 1 | — | 9.7% | — | — | 20 |
| 513 | TATT | TAT TECHNOLOGIES LTD | 1 | — | 2.2% | — | — | 20 |
| 514 | TSLA | Tesla, Inc. | 1 | — | 1.8% | — | — | 20 |
| 515 | TTI | TETRA TECHNOLOGIES INC | 1 | — | 5.9% | — | — | 20 |
| 516 | UTI | UNIVERSAL TECHNICAL INSTITUTE INC | 1 | — | 7.0% | — | — | 20 |
| 517 | VSECU | VSE CORP | 1 | — | — | — | — | 20 |
| 518 | WMT | Walmart Inc. | 1 | — | 0.9% | — | — | 20 |
| 519 | WHWK | Whitehawk Therapeutics, Inc. | 1 | — | 2.0% | — | — | 20 |
| 520 | AER | AerCap Holdings N.V. | 1 | — | 1.1% | — | — | 20 |
| 521 | BCYC | Bicycle Therapeutics plc | 1 | — | 5.6% | — | — | 20 |
| 522 | BLDR | Builders FirstSource, Inc. | 1 | — | 8.1% | — | — | 20 |
| 523 | LNG | Cheniere Energy, Inc. | 1 | — | 2.4% | — | — | 20 |
| 524 | CVLT | COMMVAULT SYSTEMS INC | 1 | — | 5.5% | — | — | 20 |
| 525 | COP | CONOCOPHILLIPS | 1 | — | 1.9% | — | — | 20 |
| 526 | CRDO | Credo Technology Group Holding Ltd | 1 | — | 5.7% | — | — | 20 |
| 527 | DDOG | Datadog, Inc. | 1 | — | 3.1% | — | — | 20 |
| 528 | DOCU | DOCUSIGN, INC. | 1 | — | 9.3% | — | — | 20 |
| 529 | ENNPF | ENBRIDGE INC | 1 | — | — | — | — | 20 |
| 530 | EQT | EQT Corp | 1 | — | 4.5% | — | — | 20 |
| 531 | XOM | EXXON MOBIL CORP | 1 | — | 1.3% | — | — | 20 |
| 532 | FHN-PH | FIRST HORIZON CORP | 1 | — | — | — | — | 20 |
| 533 | FLEX | FLEX LTD. | 1 | — | 2.9% | — | — | 20 |
| 534 | GWRE | Guidewire Software, Inc. | 1 | — | 5.2% | — | — | 20 |
| 535 | FROG | JFrog Ltd | 1 | — | 7.3% | — | — | 20 |
| 536 | KLAC | KLA CORP | 1 | — | 2.5% | — | — | 20 |
| 537 | OPTEY | Opthea Ltd | 1 | — | — | — | — | 20 |
| 538 | LIN | LINDE PLC | 1 | — | 1.2% | — | — | 20 |
| 539 | SERA | SERA PROGNOSTICS, INC. | 1 | — | 0.8% | — | — | 20 |
| 540 | VYNE | VYNE Therapeutics Inc. | 1 | — | 0.6% | — | — | 20 |
| 541 | IMA | ImageneBio, Inc. | 1 | — | — | — | — | 20 |
| 542 | IMUX | IMMUNIC, INC. | 1 | — | 7.4% | — | — | 20 |
| 543 | XOMAP | XOMA Royalty Corp | 1 | — | — | — | — | 20 |
| 544 | MSI | Motorola Solutions, Inc. | 1 | — | 1.5% | — | — | 20 |
| 545 | NVT | nVent Electric plc | 1 | — | 2.0% | — | — | 20 |
| 546 | OTIS | Otis Worldwide Corp | 1 | — | 2.9% | — | — | 20 |
| 547 | PNR | PENTAIR plc | 1 | — | 4.0% | — | — | 20 |
| 548 | IPSC | Century Therapeutics, Inc. | 1 | — | 5.6% | — | — | 20 |
| 549 | DNABW | Ginkgo Bioworks Holdings, Inc. | 1 | — | — | — | — | 20 |
| 550 | SHW | SHERWIN WILLIAMS CO | 1 | — | 1.9% | — | — | 20 |
| 551 | SNOW | Snowflake Inc. | 1 | — | 4.1% | — | — | 20 |
| 552 | ENTA | Enanta Pharmaceuticals Inc. | 1 | — | 8.9% | — | — | 20 |
| 553 | PCSC | Perceptive Capital Solutions Corp | 1 | — | 8.6% | — | — | 20 |
See where funds converge this week
Top fund moves, convergence signals, and insider buys — delivered every Monday.
Unlock AI-powered analysis explaining why each stock is scoring high — which funds are building positions, what catalysts are approaching, and how insiders are trading.
Start 7-Day Free Trial